Lange JM - Search Results

1

A comparison of serum HIV-1 RNA levels as measured by two quantitative assays in zidovudine-treated, asymptomatic, HIV-infected individuals.

Weverling GJ, Lange JM, de Jong MD, de Weerd H, Goudsmit J, de Wolf F. Weverling GJ, et al. Among authors: lange jm. Antivir Ther. 1996 Dec;1(4):255-63. Antivir Ther. 1996. PMID: 11324828 Clinical Trial.

2

Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors.

Reiss P, Casula M, de Ronde A, Weverling GJ, Goudsmit J, Lange JM. Reiss P, et al. Among authors: lange jm. HIV Med. 2004 Jan;5(1):11-4. doi: 10.1111/j.1468-1293.2004.00178.x. HIV Med. 2004. PMID: 14731163 Free article.

3

Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS.

Jurriaans S, Weverling GJ, Goudsmit J, Boogaard J, Brok M, Van Strijp D, Lange J, Koot M, Van Gemen B. Jurriaans S, et al. AIDS Res Hum Retroviruses. 1995 Apr;11(4):473-9. doi: 10.1089/aid.1995.11.473. AIDS Res Hum Retroviruses. 1995. PMID: 7632462 Clinical Trial.

4

HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.

Boucher CA, Lange JM, Miedema FF, Weverling GJ, Koot M, Mulder JW, Goudsmit J, Kellam P, Larder BA, Tersmette M. Boucher CA, et al. Among authors: lange jm. AIDS. 1992 Nov;6(11):1259-64. doi: 10.1097/00002030-199211000-00003. AIDS. 1992. PMID: 1282015

5

Long-term zidovudine treatment of asymptomatic HIV-1-infected subjects.

Mulder JW, de Wolf F, Goudsmit J, Cload PA, Coutinho RA, Fiddian AP, Schellekens PT, van der Noordaa J, Lange JM. Mulder JW, et al. Among authors: lange jm. Antiviral Res. 1990 Mar;13(3):127-38. doi: 10.1016/0166-3542(90)90028-6. Antiviral Res. 1990. PMID: 1972321

6

Markers for progression to acquired immune deficiency syndrome and zidovudine treatment of asymptomatic patients.

Lange JM, de Wolf F, Mulder JW, Coutinho RA, van der Noordaa J, Goudsmit J. Lange JM, et al. J Infect. 1989 Jan;18 Suppl 1:85-91. doi: 10.1016/s0163-4453(89)80087-8. J Infect. 1989. PMID: 2492586

7

Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects.

de Wolf F, Lange JM, Goudsmit J, Cload P, de Gans J, Schellekens PT, Coutinho RA, Fiddian AP, van der Noordaa J. de Wolf F, et al. Among authors: lange jm. Lancet. 1988 Feb 20;1(8582):373-6. doi: 10.1016/s0140-6736(88)91179-8. Lancet. 1988. PMID: 2893187 Clinical Trial.

8

Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine.

de Gans J, Lange JM, Derix MM, de Wolf F, Eeftinck Schattenkerk JK, Danner SA, Ongerboer de Visser BW, Cload P, Goudsmit J. de Gans J, et al. Among authors: lange jm. AIDS. 1988 Feb;2(1):37-40. doi: 10.1097/00002030-198802000-00006. AIDS. 1988. PMID: 3128994

9

The clinical significance of the biological phenotype of HIV.

Lange JM, de Jong MD. Lange JM, et al. AIDS Clin Rev. 1993-1994:1-18. AIDS Clin Rev. 1993. PMID: 8217894 Review. No abstract available.

10

Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.

Godfried MH, van der Poll T, Mulder JW, Weverling GJ, Endert E, Lange JM, Sauerwein HP. Godfried MH, et al. Among authors: lange jm. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15;10(5):531-9. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 8548332 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

460 results

Search Page

Filters